A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995

Scott A Hundahl, I. D. Fleming, A. M. Fremgen, H. R. Menck

Research output: Contribution to journalArticle

1337 Citations (Scopus)

Abstract

BACKGROUND. The National Cancer Data Base (NCDB) represents a national electronic registry system now capturing nearly 60% of incident cancers in the U.S. In combination with other Commission on Cancer programs, the NCDB offers a working example of voluntary, accurate, cost-effective 'outcomes management' on a both a local and national scale. In addition, it is of particular value in capturing clinical information concerning rare cancers, such as those of the thyroid. METHODS. For the accession years 1985-1995, NCDB captured demographic, patterns-of-care, stage, treatment, and outcome information for a convenience sample of 53,856 thyroid carcinoma cases (1% of total NCDB cases). This article focuses on overall 10-year relative survival and American Joint Committee on Cancer (AJCC) (3rd/4th edition) stage- stratified 5-year relative survival for each histologic type of thyroid carcinoma. Care patterns also are discussed. RESULTS. The 10-year overall relative survival rates for U.S. patients with papillary, follicular, Hurthle cell, medullary, and undifferentiated/anaplastic carcinoma was 93%, 85%, 76%, 75%, and 14%, respectively. For papillary and follicular neoplasms, current AJCC staging failed to discriminate between patients with Stage I and II disease at 5 years. Total thyroidectomy ± lymph node sampling/dissection represented the dominant method of surgical treatment rendered to patients with papillary and follicular neoplasms. Approximately 38% of such patients receive adjuvant iodine-131 ablation/therapy. At 5 years, variation in surgical treatment (i.e., lobectomy vs. more extensive surgery) failed to translate into compelling differences in survival for any subgroup with papillary or follicular carcinoma, but longer follow-up is required to evaluate this. NCDB data appeared to validate the AMES prognostic system, as applied to papillary cases. Younger age appeared to influence prognosis favorably for all thyroid neoplasms, including medullary and undifferentiated/anaplastic carcinoma. NCDB data also revealed that unusual patients diagnosed with undifferentiated/anaplastic carcinoma before age of 45 years have better survival. CONCLUSIONS. The NCDB system permits analysis of care patterns and survival for large numbers of contemporaneous U.S. patients with relatively rare neoplasms, such as thyroid carcinoma. In this context, it represents an unsurpassed clinical tool for analyzing care, evaluating prognostic models, generating new hypotheses, and overcoming the volume-related drawbacks inherent in the study of such neoplasms.

Original languageEnglish (US)
Pages (from-to)2638-2648
Number of pages11
JournalCancer
Volume83
Issue number12
DOIs
StatePublished - Dec 15 1998
Externally publishedYes

Fingerprint

Thyroid Neoplasms
Databases
Neoplasms
Carcinoma
Survival
Carcinoma, Papillary, Follicular
Oxyphil Cells
Neoplasm Staging
Thyroidectomy
Lymph Node Excision
Information Systems
Iodine
Registries
Thyroid Gland
Therapeutics
Survival Rate

Keywords

  • Adjuvant treatment
  • Anaplastic carcinoma
  • Follicular carcinoma
  • Hurthle cell carcinoma
  • Iodine-131
  • National Cancer Data Base
  • Papillary carcinoma
  • Surgery
  • Thyroid carcinoma
  • Undifferentiated carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. / Hundahl, Scott A; Fleming, I. D.; Fremgen, A. M.; Menck, H. R.

In: Cancer, Vol. 83, No. 12, 15.12.1998, p. 2638-2648.

Research output: Contribution to journalArticle

Hundahl, Scott A ; Fleming, I. D. ; Fremgen, A. M. ; Menck, H. R. / A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. In: Cancer. 1998 ; Vol. 83, No. 12. pp. 2638-2648.
@article{ae592d09c01640e8907df44028b54694,
title = "A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995",
abstract = "BACKGROUND. The National Cancer Data Base (NCDB) represents a national electronic registry system now capturing nearly 60{\%} of incident cancers in the U.S. In combination with other Commission on Cancer programs, the NCDB offers a working example of voluntary, accurate, cost-effective 'outcomes management' on a both a local and national scale. In addition, it is of particular value in capturing clinical information concerning rare cancers, such as those of the thyroid. METHODS. For the accession years 1985-1995, NCDB captured demographic, patterns-of-care, stage, treatment, and outcome information for a convenience sample of 53,856 thyroid carcinoma cases (1{\%} of total NCDB cases). This article focuses on overall 10-year relative survival and American Joint Committee on Cancer (AJCC) (3rd/4th edition) stage- stratified 5-year relative survival for each histologic type of thyroid carcinoma. Care patterns also are discussed. RESULTS. The 10-year overall relative survival rates for U.S. patients with papillary, follicular, Hurthle cell, medullary, and undifferentiated/anaplastic carcinoma was 93{\%}, 85{\%}, 76{\%}, 75{\%}, and 14{\%}, respectively. For papillary and follicular neoplasms, current AJCC staging failed to discriminate between patients with Stage I and II disease at 5 years. Total thyroidectomy ± lymph node sampling/dissection represented the dominant method of surgical treatment rendered to patients with papillary and follicular neoplasms. Approximately 38{\%} of such patients receive adjuvant iodine-131 ablation/therapy. At 5 years, variation in surgical treatment (i.e., lobectomy vs. more extensive surgery) failed to translate into compelling differences in survival for any subgroup with papillary or follicular carcinoma, but longer follow-up is required to evaluate this. NCDB data appeared to validate the AMES prognostic system, as applied to papillary cases. Younger age appeared to influence prognosis favorably for all thyroid neoplasms, including medullary and undifferentiated/anaplastic carcinoma. NCDB data also revealed that unusual patients diagnosed with undifferentiated/anaplastic carcinoma before age of 45 years have better survival. CONCLUSIONS. The NCDB system permits analysis of care patterns and survival for large numbers of contemporaneous U.S. patients with relatively rare neoplasms, such as thyroid carcinoma. In this context, it represents an unsurpassed clinical tool for analyzing care, evaluating prognostic models, generating new hypotheses, and overcoming the volume-related drawbacks inherent in the study of such neoplasms.",
keywords = "Adjuvant treatment, Anaplastic carcinoma, Follicular carcinoma, Hurthle cell carcinoma, Iodine-131, National Cancer Data Base, Papillary carcinoma, Surgery, Thyroid carcinoma, Undifferentiated carcinoma",
author = "Hundahl, {Scott A} and Fleming, {I. D.} and Fremgen, {A. M.} and Menck, {H. R.}",
year = "1998",
month = "12",
day = "15",
doi = "10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1",
language = "English (US)",
volume = "83",
pages = "2638--2648",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995

AU - Hundahl, Scott A

AU - Fleming, I. D.

AU - Fremgen, A. M.

AU - Menck, H. R.

PY - 1998/12/15

Y1 - 1998/12/15

N2 - BACKGROUND. The National Cancer Data Base (NCDB) represents a national electronic registry system now capturing nearly 60% of incident cancers in the U.S. In combination with other Commission on Cancer programs, the NCDB offers a working example of voluntary, accurate, cost-effective 'outcomes management' on a both a local and national scale. In addition, it is of particular value in capturing clinical information concerning rare cancers, such as those of the thyroid. METHODS. For the accession years 1985-1995, NCDB captured demographic, patterns-of-care, stage, treatment, and outcome information for a convenience sample of 53,856 thyroid carcinoma cases (1% of total NCDB cases). This article focuses on overall 10-year relative survival and American Joint Committee on Cancer (AJCC) (3rd/4th edition) stage- stratified 5-year relative survival for each histologic type of thyroid carcinoma. Care patterns also are discussed. RESULTS. The 10-year overall relative survival rates for U.S. patients with papillary, follicular, Hurthle cell, medullary, and undifferentiated/anaplastic carcinoma was 93%, 85%, 76%, 75%, and 14%, respectively. For papillary and follicular neoplasms, current AJCC staging failed to discriminate between patients with Stage I and II disease at 5 years. Total thyroidectomy ± lymph node sampling/dissection represented the dominant method of surgical treatment rendered to patients with papillary and follicular neoplasms. Approximately 38% of such patients receive adjuvant iodine-131 ablation/therapy. At 5 years, variation in surgical treatment (i.e., lobectomy vs. more extensive surgery) failed to translate into compelling differences in survival for any subgroup with papillary or follicular carcinoma, but longer follow-up is required to evaluate this. NCDB data appeared to validate the AMES prognostic system, as applied to papillary cases. Younger age appeared to influence prognosis favorably for all thyroid neoplasms, including medullary and undifferentiated/anaplastic carcinoma. NCDB data also revealed that unusual patients diagnosed with undifferentiated/anaplastic carcinoma before age of 45 years have better survival. CONCLUSIONS. The NCDB system permits analysis of care patterns and survival for large numbers of contemporaneous U.S. patients with relatively rare neoplasms, such as thyroid carcinoma. In this context, it represents an unsurpassed clinical tool for analyzing care, evaluating prognostic models, generating new hypotheses, and overcoming the volume-related drawbacks inherent in the study of such neoplasms.

AB - BACKGROUND. The National Cancer Data Base (NCDB) represents a national electronic registry system now capturing nearly 60% of incident cancers in the U.S. In combination with other Commission on Cancer programs, the NCDB offers a working example of voluntary, accurate, cost-effective 'outcomes management' on a both a local and national scale. In addition, it is of particular value in capturing clinical information concerning rare cancers, such as those of the thyroid. METHODS. For the accession years 1985-1995, NCDB captured demographic, patterns-of-care, stage, treatment, and outcome information for a convenience sample of 53,856 thyroid carcinoma cases (1% of total NCDB cases). This article focuses on overall 10-year relative survival and American Joint Committee on Cancer (AJCC) (3rd/4th edition) stage- stratified 5-year relative survival for each histologic type of thyroid carcinoma. Care patterns also are discussed. RESULTS. The 10-year overall relative survival rates for U.S. patients with papillary, follicular, Hurthle cell, medullary, and undifferentiated/anaplastic carcinoma was 93%, 85%, 76%, 75%, and 14%, respectively. For papillary and follicular neoplasms, current AJCC staging failed to discriminate between patients with Stage I and II disease at 5 years. Total thyroidectomy ± lymph node sampling/dissection represented the dominant method of surgical treatment rendered to patients with papillary and follicular neoplasms. Approximately 38% of such patients receive adjuvant iodine-131 ablation/therapy. At 5 years, variation in surgical treatment (i.e., lobectomy vs. more extensive surgery) failed to translate into compelling differences in survival for any subgroup with papillary or follicular carcinoma, but longer follow-up is required to evaluate this. NCDB data appeared to validate the AMES prognostic system, as applied to papillary cases. Younger age appeared to influence prognosis favorably for all thyroid neoplasms, including medullary and undifferentiated/anaplastic carcinoma. NCDB data also revealed that unusual patients diagnosed with undifferentiated/anaplastic carcinoma before age of 45 years have better survival. CONCLUSIONS. The NCDB system permits analysis of care patterns and survival for large numbers of contemporaneous U.S. patients with relatively rare neoplasms, such as thyroid carcinoma. In this context, it represents an unsurpassed clinical tool for analyzing care, evaluating prognostic models, generating new hypotheses, and overcoming the volume-related drawbacks inherent in the study of such neoplasms.

KW - Adjuvant treatment

KW - Anaplastic carcinoma

KW - Follicular carcinoma

KW - Hurthle cell carcinoma

KW - Iodine-131

KW - National Cancer Data Base

KW - Papillary carcinoma

KW - Surgery

KW - Thyroid carcinoma

KW - Undifferentiated carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0032535770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032535770&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1

DO - 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1

M3 - Article

C2 - 9874472

AN - SCOPUS:0032535770

VL - 83

SP - 2638

EP - 2648

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -